Abstract
Noninvasive treatments to treat the brain-related disorders have been paying more significant attention and it is an emerging topic. However, overcoming the blood brain barrier (BBB) is a key obstacle to most of the therapeutic drugs to enter into the brain tissue, which significantly results in lower accumulation of therapeutic drugs in the brain. Thus, administering the large quantity/doses of drugs raises more concerns of adverse side effects. Nanoparticle (NP)-mediated drug delivery systems are seen as potential means of enhancing drug transport across the BBB and to targeted brain tissue. These systems offer more accumulation of therapeutic drugs at the tumor site and prolong circulation time in the blood. In this review, we summarize the current knowledge and advancements on various nanoplatforms (NF) and discusses the use of nanoparticles for successful cross of BBB to treat the brain-related disorders such as brain tumors, Alzheimer’s disease, Parkinson’s disease, and stroke.
Highlights
Disorders in the central nervous system (CNS) creates a potential impact on public health and have remained the leading cause of death, mainly in Alzheimer’s disease (AD), Parkinson’s disease (PD), stroke, and brain tumors [1,2,3,4]
We mainly focused focused on advancements in the blood brain barrier (BBB) penetrating nanoplatforms Inthe thepresent present review, we mainly on advancements in the BBB
In addition to BBB-penetrated peptides, Monoclonal antibodies against the transferrin coated with polysorbate 80 (PBCA NPs) to deliver BBB-permeating molecular imaging contrast and insulin were conjugated theWhen surface of NPs, these antibody-conjugated agents into receptor mice brains foralso an in vivo MRIon mice were and treated with
Summary
Disorders in the central nervous system (CNS) creates a potential impact on public health and have remained the leading cause of death, mainly in Alzheimer’s disease (AD), Parkinson’s disease (PD), stroke, and brain tumors [1,2,3,4]. The detailed structure of BBB and transport mediated pathways was shown in Figure only to necessary substrates from the circulation to the brain tissue [11,12]. Thereafter, many strategies have been developed to that small lipophilic molecules (most low-o500Da) are able to cross the BBB effectively and reach the nonspecifically disrupt the and, allow the therapeutic agents to enter into the brain, but these brain [13]. Thereafter, many strategies have been developed to nonspecifically disrupt the BBB and, strategies maythe alsotherapeutic allow circulating enterinto the brain from the allow agentstoxins to enter the brain, butblood These strategies numerous may efforts allow have been attempted to develop novel strategies, which are able to deliver therapeutic drugs to CNS circulating toxins enter the brain from the blood.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
